Structure–activity studies on novel polymyxin derivatives that carry only three positive charges

Ali, 2009, Pharmacokinetics of novel antimicrobial cationic peptides NAB7061 and NAB739 in rats following intravenous administration, J Antimicrob Chemother, 64, 1067, 10.1093/jac/dkp331 Arias, 2009, Antibiotic-resistant bugs in the 21st century—a clinical super-challenge, New Engl J Med, 360, 439, 10.1056/NEJMp0804651 Boucher, 2009, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 48, 1, 10.1086/595011 Henderson, 2010, Developing an anion host for lipid A binding and antibacterial activity, Chem Commun (Camb), 46, 3197, 10.1039/b925135a Kanazawa, 2009, Contribution of each amino acid residue in polymyxin B3 to antimicrobial and lipopolysaccharide binding activity, Chem Pharm Bull, 57, 240, 10.1248/cpb.57.240 Katsuma, 2009, Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity, Chem Pharm Bull, 57, 332, 10.1248/cpb.57.332 Landman, 2008, Polymyxins revisited, Clin Microbiol Rev, 21, 449, 10.1128/CMR.00006-08 Livermore, 2009, Has the era of untreatable infections arrived?, J Antimicrob Chemother, 64, i29, 10.1093/jac/dkp255 Nation, 2009, Colistin in the 21st century, Curr Opin Infect Dis, 22, 535, 10.1097/QCO.0b013e328332e672 Pirri, 2009, Lipopeptides as anti-infectives: a practical perspective, Cent Eur J Biol, 4, 258, 10.2478/s11535-009-0031-3 Tsubery, 2001, N-terminal modifications of polymyxin B nonapeptide and their effect on antibacterial activity, Peptides, 22, 1675, 10.1016/S0196-9781(01)00503-4 Urakawa, 2010, Structure–activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides, Bioorg Med Chem Lett, 20, 1771, 10.1016/j.bmcl.2010.01.040 Vaara, 1992, Agents that increase the permeability of the outer membrane, Microbiol Rev, 56, 395, 10.1128/MMBR.56.3.395-411.1992 Vaara, 2009, New approaches in peptide antibiotics, Curr Opin Pharmacol, 9, 571, 10.1016/j.coph.2009.08.002 Vaara, 2008, Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents, Antimicrob Agents Chemother, 52, 3229, 10.1128/AAC.00405-08 Vaara, 2010, A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane, Antimicrob Agents Chemother, 54, 3341, 10.1128/AAC.01439-09 Vaara, 2010, Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampin and clarithromycin, J Antimicrob Chemother, 65, 942, 10.1093/jac/dkq040 Velkov, 2010, Structure–activity relationships of polymyxin antibiotics, J Med Chem, 53, 1898, 10.1021/jm900999h Viljanen, 1984, Susceptibility of Gram-negative bacteria to polymyxin B nonapeptide, Antimicrob Agents Chemother, 25, 701, 10.1128/AAC.25.6.701 Vingsbo Lundberg, 2010, Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice, J Antimicrob Chemother, 65, 981, 10.1093/jac/dkq072